Category: News & Comments

TCR2 Therapeutics Encouraging Oncology Results

TCR2 Therapeutics Announcement TCR2 Therapeutics ( TCRR ) - a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for cancer, announced positive interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2...

Read More

July 27, 2020

0

Atossa Genetics' news that staged a huge Rally of this small firm's stock

Atossa Genetics ( ATOS )  announced that the FDA has issued a “Safe to Proceed” letter under their “expanded access” program permitting the use of Atossa’s oral Endoxifen as a post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive (ER+) breast cancer...

Read More

March 14, 2019

0

Its All About Coronavirus

Coronavirus: The Possible Treatments While Moderna’s ( MRNA ) vaccine is being tested and its stock price continued to rise in the worst market performance day; other companies demonstrated readiness to bring their vaccines against the life-threatening virus into human...

Read More

March 19, 2020

0

Inovio: Good News About the Firm's COVID-19 Vaccine's Capability and Durability

Inovio Inovio’s COVID-19 Vaccine INO-4800 Accomplished the Following: Durable antibody and T cell responses in rhesus macaques for 4 months. Long-term protection in non-human primates challenged with SARS-CoV-2 virus 13     weeks from vaccination. No other vaccine has demonstrated...

Read More

July 30, 2020

0

The FDA approves the first ever postpartum depression product. Positive results from Dermira's atopic dermatitis product Lebrikizumab

News We Loved to Hear   The First and Only Approval of a Specific Product for Postpartum Depression ZULRESSO TM The FDA granted approval of Sage Therapeutics’ ( SAGE )  ZULRESSO TM (brexanolone) injection. A product for the treatment of...

Read More

March 20, 2019

0

Aimmune Therapeutics' product AR101 for the treatment of peanut allergy confirmed in Europe with previous successful results in the U.S.

While waiting for Mueller’s report we stopped speculating on the stocks in what we saw as an unreadable market. Following the delivery of the Mueller report we hesitated to prophesy as we waited to see how the market would perform...

Read More

March 26, 2019

0

Sangamo's stock price Soars 52% in pre-market hours on hemophilia A trial results

Sangamo's Stock Price Soars Sangamo Therapeutics' ( SGMO ) stock soared more than 52% in pre-market trading following the announcement with Pfizer ( PFE ), of interim data from Phase 1/2 Alta study evaluating the firm’s gene therapy product SB-525...

Read More

April 2, 2019

0

Regeneron and Alnylam collaborative agreement will benefit these firms so why the selloff of both?

Regeneron and Alnylam Agreement Will Benefit Both So Why the Sell-Off? Regeneron Pharmacueticals Founded, and led for 30 years, by physician-scientists   Regeneron Pharmaceuticals ( REGN ) demonstrates an exceptional ability to translate science into medicine. Working diligently Regeneron succeeded...

Read More

April 9, 2019

0

Gilead and insitro announce strategic collaboration to discover and develop novel therapies for NASH

Gilead and insitro Collaborate to Discover and Develop Novel Therapies for NASH using ISH Gilead Sciences ( GILD )   and insitro  entered into a strategic collaboration to discover and develop treatments for nonalcoholic steatohepatitis (NASH) . NASH A chronic...

Read More

April 16, 2019

0

Compugen: A Small Firm with Giant Technological Capabilities

Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting Compugen ( CGEN ) announced that it will present updates on its ongoing Phase 1 clinical trial evaluating COM701 , a first-in-class...

Read More

April 16, 2020

0

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0